Citable company snapshot
Bristol Myers Squibb's latest SEC-sourced 2026-03-31 period shows $11.49B in revenue and $2.68B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:Revenues | Mar 31, 2026 | $11.49B | $12.50B | -8.1% |
| xbrl:GrossProfit | Dec 31, 2020 | $8.16B | $8.04B | +1.5% |
| xbrl:OperatingIncomeLoss | Mar 31, 2012 | $1.40B | $1.29B | +8.9% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $2.68B | $1.09B | +146.3% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $1.10B | $1.97B | -44.1% |
| Free Cash Flow (computed) | Mar 31, 2026 | $757.00M | $1.60B | -52.8% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed Apr 30, 2026; accession 0000014272-26-000010.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
